Jan 3 (Reuters) - Agios Pharmaceuticals said on Wednesday its drug met the main and secondary goals in a late-stage study in patients with an inherited blood disorder. (Reporting by Leroy Leo in Bengaluru; Editing by Shilpi Majumdar)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.59 USD | -3.45% | -9.81% | +91.24% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+91.24% | 2.42B | |
+16.42% | 122B | |
+19.02% | 113B | |
+2.53% | 22.66B | |
-11.63% | 16.68B | |
-16.29% | 16.61B | |
-39.57% | 16.92B | |
+2.68% | 13.62B | |
+21.16% | 11.04B | |
+108.78% | 10.43B |
- Stock Market
- Equities
- AGIO Stock
- News Agios Pharmaceuticals, Inc.
- Agios' blood disorder drug meets goals of late-stage study